{
    "clinical_study": {
        "@rank": "90775", 
        "arm_group": {
            "arm_group_label": "Study Group", 
            "description": "Participants in study CYD23 (NCT00842530) with hospitalized dengue cases"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to conduct a passive surveillance of hospitalized dengue cases\n      in subjects who participated in study CYD23 (NCT00842530).\n\n      The Objectives are:\n\n        -  To describe the incidence of virologically-confirmed hospitalized dengue cases.\n\n        -  To characterize hospitalized dengue cases.\n\n        -  To evaluate the occurrence of related and fatal serious adverse events (SAEs)."
        }, 
        "brief_title": "Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Dengue", 
            "Dengue Fever", 
            "Dengue Hemorrhagic Fever"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dengue", 
                "Dengue Hemorrhagic Fever", 
                "Fever", 
                "Hemorrhagic Fevers, Viral"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will be a passive surveillance of hospitalized dengue cases in subjects who\n      participated in study CYD23 (NCT00842530) where subjects were initially randomized to\n      receive 3 injections of either CYD dengue vaccine or control at 6 month intervals. Any SAE\n      related to a study procedure or related to a previous injection from study CYD23, or any\n      fatal SAEs (even if unrelated) will be reported to the Sponsor.\n\n      An Independent Data Monitoring Committee (IDMC) will also be involved in the regular review\n      of virologically-confirmed hospitalized dengue cases. Any fatal outcome or related SAE will\n      be promptly reviewed by the IDMC.\n\n      No study vaccinations will be administered in this protocol."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ongoing participation in study CYD23 at the time of enrollment\n\n          -  Assent form has been signed and dated by the subject (for subjects \u2265 7 years old),\n             and informed consent form has been signed and dated by the parent(s) or another\n             legally acceptable representative and by 2 independent witnesses.\n\n          -  Subject and parent/legally acceptable representative are able to attend all scheduled\n             visits and to comply with all study procedures.\n\n        Exclusion Criteria:\n\n          -  Planned participation in another dengue clinical trial during the present study\n\n          -  Deprived of freedom by an administrative or court order, or in an emergency setting,\n             or hospitalized involuntarily."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Years", 
            "minimum_age": "7 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Participants in study CYD23 (NCT00842530) that are hospitalized with dengue cases."
            }
        }, 
        "enrollment": {
            "#text": "3997", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01983553", 
            "org_study_id": "CYD57", 
            "secondary_id": "U1111-1127-7380"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dengue Virus", 
            "Dengue Fever", 
            "Dengue Hemorrhagic Fever", 
            "CYD Dengue Vaccine"
        ], 
        "lastchanged_date": "November 7, 2013", 
        "link": [
            {
                "url": "http://www.sanofipasteur.com"
            }, 
            {
                "url": "http://www.sanofi.com"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Ratchaburi", 
                    "country": "Thailand", 
                    "state": "Muang District"
                }
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_groups": "1", 
        "official_title": "Long-Term Follow-Up of Hospitalized Dengue and Safety in Thai Children Who Were Included in an Efficacy Study of a Tetravalent Dengue Vaccine", 
        "overall_official": {
            "affiliation": "Sanofi Pasteur SA", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Thailand: Ministry of Public Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Case are defined as (1) An acute febrile illness with fever lasting for at least 1 day (temperature  37.5 C measured at least twice with an interval of at least 4 hours) (2) Virologically confirmed by reverse transcriptase polymerase chain reaction (RT PCR) or dengue non structural protein 1 (NS1) enzyme linked immunosorbent assay (ELISA) Antigen (Ag) test with the addition of serotype strain specific analyses where appropriate and (3) In patient hospitalization", 
            "measure": "Number of hospitalized, virologically confirmed dengue case following participation in Study CYD23", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years post vaccination in subjects who participated in study CYD23"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01983553"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Classification will be based on: (1) Detection of dengue viremia, clinical signs and symptoms, duration of clinical syndrome, duration of hospitalization, neutralizing antibody titers and other pertinent criteria (2) A severity assessment using the World Health Organization (WHO) 1997 severity definition and the IDMC severity definition and (3) A dengue serological profile based on immunoglobulin G (IgG) and IgM ELISA results in all acute febrile episodes. Neutralizing antibody titers will be assessed in all virologically confirmed dengue cases", 
                "measure": "Classification of dengue cases following participation in Study CYD23", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years post vaccination in subjects who participated in study CYD23"
            }, 
            {
                "description": "This include the occurrence, nature (MedDRA preferred term), seriousness criteria, relationship, outcome, and whether the SAE led to early termination from the study of SAEs related to study procedures or to previous injection from study CYD23 and fatal (even if unrelated) SAEs in all subjects", 
                "measure": "Number and nature of reported serious adverse events following vaccination in study CYD23", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years post vaccination in subjects who participated in Study CYD23"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi Pasteur, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}